Pinned
Slowing ageing and increasing health-span with anti-IL11 therapy
A 20 min video
Stuart Cook
1,168 posts
Stuart Cook
@stuartacook1
MD PhD. Targeting regeneration and ageing. Founder Enleofen and VVB Bio. Views my own.
- Fibroblast joke: Q: When is a fibroblast not a fibroblast? A: When it's at greater than passage 3. Not very funny. Nor is the fact that many academic, biotech and pharma labs use >P3 zombie cells Please stop Just stop Attached blot (HSCs) says it all
- The favorite wine of the western blot enthusiast. You either know Or you don’t 😉
- Six years: 2011 Write grant 2012 Grant awarded 2013 First patient recruited 2014 IL11 prioritised as pro-fibrotic protein 2015 In vitro work, file patent 2016 In vivo work, antibody development, 3 more patents 2017 Spin out company, publish results nature.com/articles/natur…
- I’ll raise you: How about a clinical trial? We have engineered a super long acting and potent anti-IL11 for human ageing trials at vvb.bio. Faster to humans, not another 5 years in mice Needs investment, build out, approvable endpoints and not easy ++. But..💰 Anyone willing to finance a study combining the latest IL11 inhibition intervention — that was just shown to extend lifespan in mice by 25% — with other interventions with the goal of finding synergistic combinations?
- From our rebuttal: "we think adding more data would over-complicate the study that already comprises six multi-panelled main figures and 15 multi-panelled supplemental figures, representing approximately 125 display items. We seek the Reviewer's understanding on this..." 😬
- Enleofen Bio Founded 2017 No VC No CEO/CSO/Canything 1 amazing employee 2 academic founders Translation at max speed Aim: publication-to-trial in <5yrs Asset acquisition in 2019 Founder Led Outsourced Biotech - it’s the future. 💥
- Is your favourite gene a drug target? 1 GnomAD - LOF + damaging nsSNP. Tolerant of variation? = safety 2 UKBB PheWas - use deleterious variants from (1). Disease in top hits? OR protective? = validation 3 Opentargets - finalise analysis Have cup of tea @ewanbirney @dgmacarthur
- 1999, my first scientific paper, 4 western blots, no supplement 2021, our latest paper, over 180 western blots, huge supplement and the reviewer asked for more Science gone mad Amazing study by the team, again IL11 strongly activates mTOR 😉
- Post COVID pulmonary fibrosis. Increasing data suggest this could be a real issue. rondepinho.com/insight/loomin…
- How does TGFB stimulate collagen and SMA translation in fibroblasts? Its taken 5 years, but we finally got there: IL11/ERK/mTOR/P70S6K is the winner For believers in JAK/STAT, its not good news And we found a new MOA for Nintedanib along the way… 👍
- We did epigenetic clock in the mice. Large effect (++). Reviewer 1 made us take it out (despite our protests - see rebuttal at Nature website). Data is shown in our online talks and on BioRxiv (I think). For sure a biomarker of interest for human trials…Replying to @MartinBJensen @aa_widjaja and @stuartacook1Has anyone done IL-11 infusions and then assessed frailty and/or DNAme clocks?
- LKB1 (STK11), a master metabolic kinase, is inhibited by IL11. The most direct example of immunometabolism to date @ImmunoMet? This links ERK (trametinib) to AMPK (metformin) and mTOR (rapamycin) - in one pathway @realNathanCheng
- Once again, the BHF front and centre in supporting my research - ever since my PhD. Extremely grateful. Much work to do in DCM and we have a GREAT team of nurses, doctors and scientists to deliver this project - working in partnership with our patients.Today the BHF is announcing a £2million study into dilated cardiomyopathy, to find new ways of diagnosing and treating people living with the condition: bit.ly/2pRl6DB
